Form 4: MIRA CEO Erez Aminov Acquires 62,500 Shares

MIRA Pharmaceuticals CEO Erez Aminov acquired 62,500 shares of common stock at $1.37 per share, increasing his direct beneficial ownership to 844,700 shares.

Summary

• Erez Aminov, Chief Executive Officer and Director of MIRA Pharmaceuticals, acquired 62,500 shares of common stock.
• The acquisition occurred on August 29, 2025, at a price of $1.37 per share.
• These shares represent Restricted Stock Units (RSUs) that vested immediately.
• The RSUs were granted under the Issuer's 2022 Omnibus Incentive Plan.
• The grant was in connection with Mr. Aminov's achievement of certain milestones as per his Executive Incentive Compensation Plan.
• Following this transaction, Mr. Aminov directly beneficially owns 844,700 shares of MIRA common stock.

Sentiment

Score: 7

Explanation: The filing indicates increased insider ownership by the CEO due to milestone achievement, which is generally a positive signal of confidence and performance. While not an open market purchase, it reflects successful execution of an incentive plan.

Positives

• CEO Erez Aminov's acquisition of 62,500 shares demonstrates increased insider ownership, which can signal confidence in the company's future prospects.
• The RSU grant is tied to the achievement of specific milestones under an Executive Incentive Compensation Plan, indicating successful performance by the CEO.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the RSU grant tied to milestone achievement suggests a positive outlook on the CEO's past performance and continued alignment with company goals.

Industry Context

Insider buying, especially by a CEO, is often viewed positively by the market as it signals management's belief in the company's value and future growth, aligning their interests with shareholders. This is a standard practice in executive compensation plans across various industries to incentivize performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of an Executive Incentive Compensation Plan is a common practice in the pharmaceutical and biotechnology industries, aligning executive pay with performance milestones.
• The immediate vesting of RSUs upon milestone achievement is also a standard mechanism to reward specific, pre-defined accomplishments, similar to practices seen in companies like Pfizer or Moderna for executive performance bonuses.
• The reported beneficial ownership of 844,700 shares by the CEO, Erez Aminov, represents a significant stake, comparable to the ownership levels of key executives in small to mid-cap pharmaceutical companies, indicating strong personal investment in the company's success.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to CEO's increased stake and achievement of performance milestones, potentially signaling positive future performance.
• Employees: May view the CEO's compensation tied to milestones as a positive example of performance-based rewards within the company.

Key Dates

Recommendation

While the CEO's increased beneficial ownership due to RSU vesting is a positive signal of confidence and performance, it is a pre-planned compensation event rather than an open market purchase. It reinforces alignment but does not introduce new, unexpected information that would warrant a 'buy' or 'strong buy' recommendation solely based on this filing. Investors should 'hold' and consider this as a confirmation of ongoing executive alignment and performance against internal milestones, while awaiting broader financial and strategic updates.

Keywords

MIRA Pharmaceuticals, MIRA, Erez Aminov, Insider Trading, Form 4, Stock Acquisition, CEO, Restricted Stock Units, RSU, Executive Compensation, Beneficial Ownership